Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 03, 2015 8:52 AM ET


Company Overview of Viamet Pharmaceuticals, Inc.

Company Overview

Viamet Pharmaceuticals, Inc. discovers and develops novel antifungal agents through a proprietary medicinal chemistry platform. Its product includes VT-1161, an oral agent that is in Phase IIa clinical trials for the treatment of moderate to severe acute vulvovaginal candidiasis; and moderate to severe interdigital tinea pedis, a dermatologic infection. The company is also developing VT-1129, an oral agent for the treatment of cryptococcal meningitis, an invasive fungal infection of the lining of the brain and spinal cord; and VT-1598 and related analogues, which are in preclinical development to identify the optimal candidate to advance in development as an oral and intravenous therapy for ...

4505 Emperor Boulevard

Suite 300

Durham, NC 27703

United States





Key Executives for Viamet Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 53
Chief Business & Financial Officer
Age: 50
Chief Development Officer
Compensation as of Fiscal Year 2014.

Viamet Pharmaceuticals, Inc. Key Developments

Viamet Pharmaceuticals, Inc. Announces Initiation of REVIVE Phase 2b Study of VT-1161 in Recurrent Vulvovaginal Candidiasis

Viamet Pharmaceuticals, Inc. announced the initiation of the REVIVE (REcurrent Vulvovaginal Candidiasis Inhibition; an Oral VT-1161 Tablet Evaluation) Phase 2b clinical trial of VT-1161 for the treatment of recurrent vulvovaginal candidiasis (RVVC), a particularly refractory clinical condition. VT-1161 is a novel, orally-available, highly potent and selective inhibitor of fungal CYP51, a well validated antifungal target. As previously reported by Viamet, VT-1161 demonstrated robust antifungal activity and a favorable safety profile in a Phase 2a proof-of-concept study in the treatment of acute vulvovaginal candidiasis. REVIVE, which is a randomized, double-blind, placebo-controlled study, will enroll approximately 200 patients with a documented history of RVVC at approximately 25 clinical sites throughout the U.S. The study will evaluate two dose levels of VT-1161 administered once-weekly for either 11 or 23 weeks following an initial one-week loading-dose period. The primary endpoint for the study will be the prevention of acute episodes of vulvovaginal candidiasis through week 48 of the study, which extends either 24 or 36 weeks beyond the conclusion of dosing with VT-1161 depending on the dose group. An estimated 5-8% of women of child-bearing age suffer from recurring episodes of acute vulvovaginal candidiasis, a syndrome termed RVVC. There are currently no approved agents in the United States to prevent these recurring and difficult to treat infections. Current therapies, while effective for uncomplicated episodes of acute vulvovaginal candidiasis, are typically not effective in preventing recurrent infections. There is a significant unmet medical need for a safe and effective oral therapy to treat RVVC.

Viamet Pharmaceuticals, Inc. Presents at CED Life Science Conference 2015, Mar-03-2015 01:15 PM

Viamet Pharmaceuticals, Inc. Presents at CED Life Science Conference 2015, Mar-03-2015 01:15 PM. Venue: Raleigh Convention Center, Raleigh, North Carolina, United States. Speakers: Robert J. Schotzinger, Chief Executive Officer, President and Director.

Viamet Announces Appointment of Amir Tavakkol as Chief Development Officer

Viamet Pharmaceuticals, Inc. announced the appointment of Amir Tavakkol, Ph.D., as Chief Development Officer. Dr. Tavakkol brings over 25 years of experience in pharmaceuticals, consumer healthcare and academia, including substantial expertise in the clinical development of novel antifungal products for superficial as well as systemic indications. Dr. Tavakkol will have significant responsibility for the management of Viamet's clinical programs, including the ongoing clinical development of VT-1161, the Company's lead novel, oral antifungal compound. Prior to joining Viamet, Dr. Tavakkol most recently served as Senior Vice President of Clinical Development & Operations at Topica Pharmaceuticals Inc.

Similar Private Companies By Industry

Company Name Region
Actavis Totowa LLC United States
SmithKline Beecham Holdings Corporation United States
Wyeth Ayerst Pharmaceuticals United States
Global Biotechnologies, Inc. United States
Jiva Pharma, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Viamet Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at